Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients

American Journal of Pathology

Volumn 153, Issue 3, 1998, Pages 973-983

  Huang, Cheng Iong ^a   Kohno, Nobuoki ^b   Ogawa, Eiji ^a   Adachi, Masashi ^a   Taki, Toshihiko ^a   Miyake, Masayuki ^a  

^a Kitano Hospital   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD9 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEGMENTAL MASTECTOMY; STATISTICAL ANALYSIS;

EID: 0031683674     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65639-8     Document Type: Article

References (43)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992, 339:1-15,71-85
2. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993, 85:200-206
3. Hartmann LC, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Cancer 1994, 74:2956-2963
4. Giai M, Roagna R, Ponzone R, Bortoli MD, Dati C, Sismondi P: Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994, 14:1441-1450
5. Berns EMJJ, Klijn JGM, Smid M, Staveren IL. Look MP, Putten WLJ, Foekens JA: TP53, and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer 1996, 16:170-179
6. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ: Oncogene protein co-expression: value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995, 221: 706-720
7. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value Proc Natl Acad Sci USA 1996, 93:1093-1096
8. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M: Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 1993, 177:1231-1237
9. Miyake M, Nakano K, Ieki Y, Adachi M, Huang C, Itoi S, Koh T, Taki T: Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res 1995, 55:4127-4131
10. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995, 268: 884-886
11. Radford KJ, Mallesch J, Hersey P: Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer 1995, 62:631-635
12. Miyake M, Koyama M, Seno M. Ikeyama S: Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J Exp Med 1991, 174:1347-1354
13. Miyake M, Nakano K, Itoi S, Koh T, Taki T: Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 1996, 56:1244-1249
14. Higashiyama M, Taki T, Ieki Y, Adachi M, Huang C, Koh T, Kodama K, Doi O, Miyake M: Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 1995, 55:6040-6044
15. Gaugitsch HW, Hofer E, Huber NE, Schnabl E, Baumruker T: A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23. Eur J Immunol 1991, 21:377-383
16. Yang X, Welch DR, Phillips KK, Weissman BE, Wei LL: KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett 1997, 119:149-155
17. Phillips KK, White AE, Hicks DJ, Welch DR, Barrett JC, Wei LL, Weissman BE: Correlation between reduction of metastasis in the MDA-MB-435 model system and increased expression of the Kai-1 protein. Mol Carcinog 1998, 21:111-120
18. Adachi M, Taki T, Ieki Y, Huang C, Higashiyama M, Miyake M: Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer Cancer Res 1996, 56:1751-1755
19. Hotta H, Ross AH, Huebner K, Isobe M, Wendeborn S, Chao MV, Ricciardi RP, Tsujimoto Y, Croce CM, Koprowski H: Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res 1988, 48:2955-2962
20. Hermanek P, Sobin LH: TNM Classification of Malignant Tumors, ed 4. Edited by P Hermanek, LH Sobin. Berlin, Springer-Verlag, 1987, pp 103-109
21. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159
22. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T: Molecular structure of the human cytoplasmic β-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 1985, 82:6133-6137
23. Takahasi K, Sawasaki Y: Rare spontaneously transformed human endothelial cell line provides useful research tool. In Vitro Cell Dev Biol 1992, 28A:380-382
24. Coen DM: Quantitation of rare DNAs by PCR. Current Protocols in Molecular Biology. Edited by FM Ausubel, R Brent, RE Kingston, DD Moore, JG Seidman, JA Smith, K Struhl. New York, John Wiley & Sons, 1995, pp 15.3.1-15.3.8
25. Huang C, Taki T, Adachi M, Yagita M, Sawada S, Takabayashi A, Inufusa H, Yoshie O, Miyake M: MRP-1/CD9 and KAI1/CD82 expression in normal and various cancer tissues. Int J Oncol 1997, 11:1045-1051
26. Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N, Nishimura M, Hinuma Y, Yoshie O: C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J Immunol 1992, 149:2879-2886
27. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigler HF, McCarty KS Sr: Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986, 46:4244s-4248s
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481
29. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170
30. Cox DR: Regression models and life-tables. J R Stat Soc B 1972, 34:187-220
31. Oren R, Takahashi S, Doss C, Levy R, Levy S: TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 1990, 10:4007-4015
32. Amiot M: Identification and analysis of cDNA clones encoding CD53: a pan-leukocyte antigen related to membrane transport proteins. J Immunol 1990, 145:4322-4325
33. Classon BJ, Williams AF, Willis AC, Seed B, Stamenkovic I: The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OX-44 antigen. J Exp Med 1989, 169: 1497-1502
34. Wright MD, Tomlinson MG: The ins and outs of the transmembrane 4 superfamily. Immunol Today 1994, 15:588-594
35. Hemler ME, Mannion BA, Berditchevski F: Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta 1996, 1287:67-71
36. Rubinstein E, Naour FL, Lagaudriere-Gesbert C, Billard M, Conjeaud H, Boucheix C: CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR, and VLA integrins. Eur J Immunol 1996, 26:2657-2665
37. Berditchevski F, Zutter MM, Hemler ME: Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). Mol Biol Cell 1996, 7:193-207
38. Mannion BA, Berditchevski F, Kraeft SK, Chen LB, Hemler ME: Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associate with integrin α4β1 (CD49d/CD29). J Immunol 1996, 157:2039-2047
39. Angelisova P, Hilgert I, Horejsi V: Association of four antigens of the tetraspans family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II glycoproteins. Immunogenetics 1994, 39:249-256
40. Szollosi J, Horejsi V, Bene L, Angelisova P. Damjanovich S: Supramolecular complexes of MHC class I. MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol 1996, 157:2939-2946
41. 2-microglobulin complexes. J Immunol 1997, 158:2790-2797
42. Cajot JF, Sordat I, Silvestre T, Sordat B: Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res 1997, 57:2593-2597
43. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT: Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996, 56:4387-4390